Global Solid Tumor Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2028-Growing prevalence of various types of cancer, rising approvals of new drugs for the treatment and increasing research & development activities are some factors driving the growth of global solid tumor treatment market.
Global Solid Tumor Treatment Market is valued at USD 146.75 Billion in 2021 and expected to reach USD 310.49 Billion by 2028 with a CAGR of 11.30% over the forecast period.
A solid tumor is a strange mass or piece of tissues without fluid or cysts. It doesn’t require that tumor should always be cancerous. Therapy for solid tumors generally joins a few kinds of treatment, which might incorporate chemotherapy, surgery, and radiation treatment. To make the best treatment plan, the group needs data about patient’s explicit cancer, including its location and size. Doctors frequently get this data in many ways. They incorporate tests like a CT, MRI or bone scan, or a surgical biopsy. Chemotherapy is predominantly joined with a surgery and radiation for solid tumors. Solid tumor treatments treat lung, prostate, breast, colorectal, and cervical cancers. The worldwide oncology market shows strong tumor treatments are the best efficient anti-cancer treatments.
The COVID-19 pandemic has negative impact on the global solid tumor treatment market. The types of cancer treatment practices are being influenced because of COVID-19 pandemic. During COVID-19 pandemic, most of the surgeries and appointments of cancer treatment get cancelled to reduce the risk of infection. However, the quantity of remote consultations directed during various periods of the pandemic. Initiatives Pharma organizations can give oncology experts to help them deliver the most ideal consideration to their patients, presently and in the new normal.
The global solid tumor treatment market is segmented based on therapy, cancer type, end-user, and region & country level. Based on the therapy, the global solid tumor treatment market is classified into immunotherapy, chemotherapy, radiotherapy, targeted therapy, and hormone therapy. Based on the cancer type, the market is classified into breast cancer, lung cancer, cervical cancer, colorectal cancer, prostate cancer, and others. Based on the end-user, the global solid tumor treatment is classified into hospital and cancer treatment centers.
The regions covered in global solid tumor treatment market report are North America, Europe, Asia-Pacific, Latin America, and Rest of the World. Based on country level, the market of global solid tumor treatment is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.
Key Players for Global Solid Tumor Treatment Report-
Some major key players in the global solid tumor treatment market report cover prominent players like Johnson & Johnson Company, Biogen Idec Incorporated, Abbott Laboratories Inc., Baxter International Incorporated, AstraZeneca Plc., Amgen Inc., GlaxoSmithKline Plc., Bristol Myers Squibb Company, Sanofi, and others.
Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
On May 5th, 2022; AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) had endorsed in the US for the therapy of grown-up patients with unrespectable or metastatic HER2-positive breast cancer who have gotten an earlier anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have created illness repeat during or in something like a half year of finishing treatment. The endorsement by the Food and Medication Organization (FDA) dependent on positive outcomes from the Fate Breast03 Stage III preliminary that showed Enhertu decreased the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unrespectable as well as metastatic breast cancer recently treated with trastuzumab and a taxane.
FDA Approved Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer
On October 13th, 2021; The Food and Medication Organization had approved pembrolizumab (Keytruda, Merck) in blend with chemotherapy, despite everything bevacizumab, for patients with persistent, repetitive, or metastatic cervical cancer whose growths express PD-L1 (CPS), not entirely settled by an FDA-endorsed test. FDA likewise conceded normal approval to pembrolizumab as a solitary specialist for patients with intermittent or metastatic cervical cancer with disease movement on or after chemotherapy whose cancers express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Growing prevalence of various types of cancer, rising approvals of new drugs for the treatment, and increasing research & development activities are some factors driving the growth of Global Solid Tumor Treatment Market
One of the major factors driving the growth of the global solid tumor treatment market is growing prevalence of various types of cancer. The Solid tumors could occur in numerous places like bone, muscle, and organs. Hence, the increasing cases of various cancers drive the development of global solid tumor treatment market over the forecast period. For instance, according to the World Health Organization (WHO), Cancer is a main cause of death around the world, represented almost 10 million deaths in 2020. There are about 2.26 million breast cancer cases and about 2.21 million lung cancer patients globally. In addition, another major factor for the growth of the global solid tumor treatment market is due to rising approvals of new drugs for the treatment. For example, as per the news published on June 29th, 2020, the U.S. Food and Drug Administration approved Keytruda (pembrolizumab) for intravenous injection for the first-line therapy of patients with unrespectable or metastatic microsatellite instability-high (MSI-H) or confound fix lacking (dMMR) colorectal cancer.
Furthermore, the increasing research & development activities also drive the global solid tumor treatment market. The number of government organizations is expanding funding for healthcare infrastructure framework, which will influence market dynamics. Rising public and private initiatives to bring awareness and demand for successful chemotherapeutic specialists will develop the solid tumors market. However, the high cost of the therapy & associated side effects like hair loss, anemia, and skin reactions may hamper the global solid tumor treatment market growth. Despite that, growing advancement in treatment techniques provide various opportunities for the further growth of the global solid tumor treatment market over the forecast period.
North America expected to dominate the Global Solid Tumor Treatment Market
North America is expected to dominate the global solid tumor treatment market due to the growing incidences of cancer, growing awareness among people and presence of key players. As the number of various cancer patients increases that drive solid tumor treatment market over the forecast period. For instance, as per the American Cancer Society, in 2022, there will be an expected 1.9 million new disease cases analyzed and 609,360 cancer passings in the United States. Also, growing government support for innovative treatment drives the solid tumor market in the region. For example, as per the news published on May 28th, 2021, the U.S. Food & Drug Administration approved Lumakras (sotorasib) as the primary therapy for grown-up patients with non-small cell lung cancer whose tumors have a particular type of genetic mutation called KRAS G12C and who have approved at least one prior systemic therapy. This is the initial approved targeted treatment for tumors with any KRAS mutation, which accounts for around 25% of mutations in non-small cell lung cancers.
The Asia Pacific is anticipated to grow faster in the global solid tumor treatment market within the forecast period due to increasing breast cancer cases, rising awareness regarding cancer, and increasing healthcare infrastructure. Increasing breast cancer cases in the region drive the solid tumor treatment market over the forecast period. For example, according to the 2020 National Cancer Registry Program Report, in 2020, there are about 2 lakh ladies in India were assessed to have been diagnosed with breast cancer, and more than 76,000 deaths were reported. The number is supposed to increase to more than 2.3 lakh cases in 2025.
Key Benefits for Global Solid Tumor Treatment Market Report–
Global Solid Tumor Treatment Market Segmentation-
By Cancer Type:
By Cancer Type:
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®